Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABCL646
- Development stage
- Preclinical
- Lead developer
- AbCellera Biologics
- Modality
- Antibody-Based Therapeutics
01
Overview
ABCL646 is an investigational, preclinical antibody drug candidate being developed by AbCellera. It is designed as a potential first-in-class antibody antagonist targeting an undisclosed ion channel. The program was announced in November 2026 alongside AbCellera's Q3 2026 financial results and is currently undergoing IND-enabling activities. Due to its early stage of development, the specific therapeutic indications and the exact ion channel target have not been disclosed by the company.
Beyond the preview
Go deeper on ABCL646.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABCL646.
Work on ABCL646? Claim this page to correct or add information. Claim this page